Abstract:Background Anticoagulants are the main drugs used for the prevention and treatment of thrombosis. Currently, anticoagulant drugs are primarily multitarget heparin drugs, single-target FXa inhibitors and FIIa inhibitors. In addition, some traditional Chinese drugs also have anticoagulant effects, but they are not the main direction of treatment at present. But the anticoagulant drugs mentioned above, all have a common side effect is bleeding. Many other anticoagulation targets are under investigation. With further exploration of coagulation mechanism, how to further determine new anticoagulant targets and how to make traditional Chinese medicine play anticoagulant role have become a new field of exploration. Purpose The purpose of the study was to summarize the recent research progress on coagulation mechanisms, new anticoagulant targets and traditional Chinese medicine. Methods A comprehensive literature search was conducted using four electronic databases, including PubMed, Embase, CNKI, Wanfang database and ClinicalTrials.gov, from the inception of the study to 28 Feb 2023. Key words used in the literature search were "anticoagulation", "anticoagulant targets", "new targets", "coagulation mechanisms", "potential anticoagulant", "herb medicine", "botanical medicine", "Chinese medicine", "traditional Chinese medicine", "blood coagulation factor", keywords are linked with AND/OR. Recent findings on coagulation mechanisms, potential anticoagulant targets and traditional Chinese medicine were studied. Results The active components extracted from the Chinese medicinal herbs, Salvia miltiorrhiza, Chuanxiong rhizoma, safflower and panax notoginseng have obvious anticoagulant effects and can be used as potential anticoagulant drugs, but the risk of bleeding is unclear. TF/FVIIa, FVIII, FIX, FXI, FXII, and FXIII have all been evaluated as targets in animal studies or clinical trials. FIX and FXI are the most studied anticoagulant targets, but FXI inhibitors have shown stronger advantages. Conclusion This review of potential anticoagulants provides a comprehensive resource. Literature analysis suggests that FXI inhibitors can be used as potential anticoagulant candidates. In addition, we should not ignore the anticoagulant effect of traditional Chinese medicine, and look forward to more research and the emergence of new drugs.

Discovering peptide inhibitors of thrombin as a strategy for anticoagulation

Factor Ⅺ-a promising anticoagulation target

New Medicine for Antithrombotic Treatment of Atrial Fibrillation—Who Can Dominate in the Future

A Novel Hirudin Derivative Inhibiting Thrombin Without Bleeding for Subcutaneous Injection.

RGD-hirudin-based low molecular weight peptide prevents blood coagulation via subcutaneous injection

The Research Progress of Direct Thrombin Inhibitors

Anti-thrombotic Effects Mediated by a Novel Dual-Target Peptide Inhibiting Both Platelet Aggregation and Thrombin Activity without Causing Bleeding

Discovery and development of Factor Xa inhibitors (2015-2022)

Therapeutic effects and molecular mechanisms of natural products in thrombosis

Factor XI, a potential target for anticoagulation therapy for venous thromboembolism

Thrombin and Thrombin‐Incorporated Biomaterials for Disease Treatments

An Update on Safe Anticoagulation.

Factor XI: structure, function and therapeutic inhibition

Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs

Improving the understanding of plasma kallikrein contribution to arterial thrombus formation using two plant protease inhibitors

The third-generation anticoagulants: factors XI, XII, and XIII inhibitors

Intracerebral hemorrhage and thrombin-induced alterations in cerebral microvessel matrix

Regulation of thrombin activity with a bifunctional aptamer and hemin: development of a new anticoagulant and antidote pair.

Discovery and Characterization of Panaxatriol as a Novel Thrombin Inhibitor from Panax notoginseng Using a Combination of Computational and Experimental Approaches

Potential Anticoagulant of Traditional Chinese Medicine and Novel Targets for Anticoagulant Drugs

Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests